Abstract Purpose of the Review Acid suppression with proton pump inhibitors (PPIs)
represents the standard of care in the treatment of acid-related diseases. However, despite …

Description The purpose of this American Gastroenterological Association (AGA) Institute
Clinical Practice Update (CPU) is to summarize the available evidence and offer expert Best …

ABSTRACT Introduction Proton pump inhibitors (PPIs) are the first-line treatment for
gastroesophageal reflux disease (GERD). However, due to their intrinsic limitations, there …

This systematic review and meta-analysis evaluated the efficacy of dexlansoprazole (a
proton pump inhibitor—PPI) in resolving heartburn, reflux, and other symptoms and …

As the rate of discovery of drug-resistant Helicobacter pylori cases increases worldwide, the
relevant societies have updated their guidelines for primary eradication regimens. A …

Abstract Background and Aims Acid‐suppressive drugs (ASDs) are widely used in many
gastric acid‐associated diseases. Nocturnal acid breakthrough has been a common …

Background: Proton-pump inhibitors (PPIs) and potassium-competitive acid blockers (P-
CABs) are recommended for erosive esophagitis (EE), with good safety and tolerance …

Abstract Background In Chinese healthcare settings, drug selection decisions are
predominantly influenced by the Pharmacy & Therapeutics Committee (PTC). This study …

Aims The new modified‐release formulation of tegoprazan, a novel potassium‐competitive
acid blocker, is expected to improve the management of acid‐related disease, including …

METHODS: A phase III, multicenter, randomized, double-blind, non-inferiority clinical study
was conducted with 300 subjects with confirmed EE. Subjects were randomized to receive …